CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	12 Months Ended		63 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (2,582,537)	$ (2,363,344)	$ (12,131,283)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	185,271	211,709	976,734
Technology impairment	345,000	345,000	690,000
Common stock issued for services	18,500	0	318,500
Stock options and warrants	63,385	382,918	3,013,752
(Increase) decrease in assets
Grants receivable	0	244,479	0
Prepaid drug product for testing	(42,000)	(64,600)	(195,000)
Other current assets	5,864	24,554	(42,575)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	13,113	69,373	329,244
Net cash used in operating activities	(1,993,404)	(1,149,911)	(7,040,628)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	(25,000)	(170,056)	(884,710)
Net cash used in investing activities	(25,000)	(170,056)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	1,600,198	2,033,654	8,039,384
Net cash from financing activities	1,600,198	2,033,654	8,459,384
NET INCREASE (DECREASE) IN CASH	(418,206)	713,687	534,046
Cash, beginning of period	952,252	238,565	0
Cash, end of period	534,046	952,252	534,046
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	0	179,421	591,566
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 1,750	$ 1,549	$ 210,755